Kennedy vs. AAP: COVID Shots for Kids Debate
Shifting Sands in Childhood Vaccination: AAP and CDC Diverge on COVID-19 Shots
The American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC) are exhibiting a notable divergence in their recommendations for childhood coronavirus vaccinations, a shift occurring amidst a summer increase in COVID-19 cases and uncertainty surrounding future vaccine access. This change is further intricate by recent personnel changes within the CDC’s advisory panel and concerns over insurance coverage.
The Core of the Disagreement
While the CDC has softened its recommendation to an annual coronavirus shot for all children,suggesting parents consult with a doctor,the AAP has issued a broader recommendation. The AAP now advises that healthy children ages 2 to 18 can receive a coronavirus vaccine if their parents desire it. This difference stems from a fundamental disagreement on risk assessment and the value of universal vaccination.
Robert F. Kennedy Jr., who recently appointed a new Advisory Committee on Immunisation Practices (ACIP) with members critical of widespread coronavirus vaccination, has publicly criticized the AAP, labeling their recommendations as “corporate-friendly” and alleging conflicts of interest due to donations from vaccine manufacturers. He called for full disclosure of thes “corporate entanglements.”
Vaccination Rates and the Rationale Behind the AAP’s Stance
Current vaccination rates among children are low. The CDC estimates that only 13% of eligible children are up-to-date on their coronavirus vaccines, with rates even lower (4.5%) for children under 23 months. Despite these low rates, the AAP argues that offering the vaccine is crucial, particularly as a little over half of children aged 6 months to 23 months admitted to intensive care with COVID-19 between October 2022 and April 2024 had no underlying health conditions.
Paediatric infectious-disease specialists maintain that regular vaccination of children is a sound public health strategy, as protection levels mirror those seen in adults.
The Role of the New ACIP and Insurance Coverage
The revamped ACIP, appointed by Kennedy, has not yet issued any coronavirus recommendations. Its first meeting in late June did not address the issue, and a special meeting is not anticipated before mid-September, a timeline further complicated by the August 8 shooting at the CDC headquarters. The regularly scheduled ACIP meeting is in October.
A key concern is insurance coverage. Under federal law, vaccinations recommended by the ACIP are covered by insurers. The AAP is actively engaging with insurance companies to ensure continued coverage based on professional association guidance, even without a federal ACIP recommendation. Initial signals from insurers, including America’s Health Insurance Plans (Ahip), suggest a willingness to continue covering respiratory virus vaccines.
Data on Vaccine Effectiveness and Future Outlook
Limited data from the CDC indicates that the 2024-2025 coronavirus vaccines offered increased protection against severe illness in both children and adults. Though, measuring vaccine effectiveness in young children is challenging due to the low vaccination rates.
The Food and Drug Administration (FDA) has signaled it will not license upcoming coronavirus vaccines for otherwise healthy children. The AAP’s full vaccine guidance, published in its clinical guidebook, aligns with federal recommendations for other diseases like influenza and RSV.
| Vaccination Status | Severe Illness Protection (2024-2025 Vaccine) |
|---|---|
| Vaccinated | Increased Protection |
| Unvaccinated | Lower Protection |
Where,When,and Why It Matters
- Where: United States
- When: Summer/Fall 2024 (ongoing developments)
- Why: diverging recommendations from key health organizations create confusion for parents and potentially impact public health efforts to control COVID-19. The changes also highlight a growing politicization of vaccine policy.
What’s Next
The coming months will be critical. the ACIP’s eventual recommendations, the FDA’s licensing decisions, and the continued negotiations with insurance companies will determine the future of childhood coronavirus vaccination in the US. The CDC’s ability to recover from the August 8th shooting and resume normal operations will also play a role.